Recurrent and partially reversible cardiomyopathy occurring during treatment with bendamustine and rituximab

Bendamustine (B) is an anti-neoplastic agent with dual pharmacologic properties resembling both alkylating agents and purine analogs. It is approved by the United States Food and Drug Administratio...